Clinical Practice Recommendations of the Swiss Society for Neuroradiology: Neuroimaging Standards for Enrollment and Disease Monitoring in Anti-Amyloid Immunotherapies
Neurodegenerative Diseases · 2025
DOI: 10.1159/000549521 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurodegenerative Diseases, 2025. Verfasst von Roland Wiest und 9 weiteren Autor:innen. Beteiligte Einrichtung: University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Neuroimaging, Immunotherapy, Alzheimer Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The Swiss Society for Neuroradiology (SSNR) has established clinical practice recommendations to guide the use of neuroimaging in the enrollment and treatment monitoring of patients undergoing anti-amyloid immunotherapies for Alzheimer’s disease. In Switzerland, anti-amyloid immunotherapy (AAT) has not been approved by Swissmedic ahead of this publication. This paper therefore reflects the existing international standards of care and will be updated after market clearance of AATs in Switzerland. Background and Rationale: Neuroimaging is a key requirement to assess therapeutic responses and manage potential adverse effects, particularly amyloid-related imaging abnormalities (ARIAs). The SSNR recommendations specify the appropriate use of magnetic resonance imaging biomarkers to support therapy inclusion, routine monitoring, and decision-making in case of manifestations of ARIA-E and ARIA-H during treatment.
Conclusions
This paper reviews the required imaging protocols and criteria for patient eligibility and discusses the key findings of ARIA-E and ARIA-H. These findings should be detected and interpreted by the practicing radiologist to ensure patient safety. The practice recommendations of the SSNR align with previous published recommendations of the American Society of Neuroradiology. On this basis, we also provide practical recommendations for workflows and candidate selection to continue or discontinue therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Translational Imaging Center (TIC), Swiss Institute for Translational and Entrepreneurial Medicine, Bern, Switzerland.
- Diagnostic and Interventional Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
- Mallinckrodt Institute of Radiology, Neuroradiology Division, Washington University School of Medicine, St Louis, Missouri, USA.
- Department of Radiology, Neuroradiology Division, Northwell Health, New York, New York, USA.
- Neuroradiology Hirslanden, Zurich, Switzerland.
Zitieren
APA
Wiest, R., Radojewski, P., Lieb, J. M., Psychogios, M., Benzinger, T. L. S., Franceschi, A. M., Wanke, I., Draganski, B., Kurz, F. T., & Lövblad, K. O. (2025). Clinical Practice Recommendations of the Swiss Society for Neuroradiology: Neuroimaging Standards for Enrollment and Disease Monitoring in Anti-Amyloid Immunotherapies. Neurodegenerative Diseases. https://doi.org/10.1159/000549521
Vancouver
Wiest R, Radojewski P, Lieb JM, Psychogios M, Benzinger TLS, Franceschi AM, et al. Clinical Practice Recommendations of the Swiss Society for Neuroradiology: Neuroimaging Standards for Enrollment and Disease Monitoring in Anti-Amyloid Immunotherapies. Neurodegenerative Diseases. 2025. doi:10.1159/000549521
BibTeX
@article{Wiest2025,
author = {Wiest, Roland and Radojewski, Piotr and Lieb, Johanna Maria and Psychogios, Marios and Benzinger, Tammy Lee Smith and Franceschi, Ana M and Wanke, Isabel and Draganski, Bogdan and Kurz, Felix T and Lövblad, Karl-Olof},
title = {Clinical Practice Recommendations of the Swiss Society for Neuroradiology: Neuroimaging Standards for Enrollment and Disease Monitoring in Anti-Amyloid Immunotherapies},
journal = {Neurodegenerative Diseases},
year = {2025},
doi = {10.1159/000549521}
}
EUVIMED